keyword
https://read.qxmd.com/read/38514211/biomarkers-of-minimal-residual-disease-and-treatment
#21
JOURNAL ARTICLE
Nigel P Murray
Minimal residual disease (MRD) has been defined as a very small numbers of cancer cells that remain in the body after curative treatment. Its presence or absence will ultimately determine prognosis. With the introduction of new technologies the presence of MRD in patients with solid tumours can be detected and characterized. As MRD predicts future relapse, be it early or late treatment failure, in an otherwise asymptomatic patient its treatment and when to start treatment remains to be determined. Thus the concepts of personalized medicine using different biomarkers to classify the biological properties of MRD maybe come possible...
2024: Advances in Clinical Chemistry
https://read.qxmd.com/read/38481938/evaluating-circulating-tumour-cell-enrichment-techniques-to-establish-an-appropriate-method-for-clinical-application-in-glioblastomas
#22
JOURNAL ARTICLE
Hannah R Barber, Claire M Perks, Kathreena M Kurian
Brain tumours reduce life expectancy for an average of 20 years per patient, the highest of any cancer. A third of brain tumour patients visit their GP at least five times before diagnosis and many of those are diagnosed late through emergency departments. A possible solution to this challenge is to utilise a "liquid biopsy" blood test designed for circulating tumour cells (CTCs). Such a test could be applied at a primary healthcare centre, contributing to informed decision making for diagnostic imaging referrals...
2024: Frontiers in Neurology
https://read.qxmd.com/read/38479442/a-systematic-review-of-circulating-predictive-and-prognostic-biomarkers-to-aid-the-personalised-use-of-radiotherapy-in-the-radical-treatment-of-patients-with-oesophageal-cancer
#23
JOURNAL ARTICLE
Dylan McClurg, Chandan Sanghera, Somnath Mukherjee, Rebecca C Fitzgerald, Christopher M Jones
BACKGROUND: The availability of circulating biomarkers that are predictive of treatment response or prognostic of overall outcome could enable the personalised and adaptive use of radiotherapy (RT) in patients with oesophageal adenocarcinoma (OAC) and squamous cell carcinoma (OSCC). METHODS: A systematic review was carried out following Preferred Reporting Items for Systematic Reviews guidance. Medline, EMBASE, PubMed, Cochrane Library, CINAHL, Scopus and the Web of Science databases were searched for studies published between January 2005-February 2023 relating to circulating biomarkers evaluated in the context of neoadjuvant or definitive RT delivered for OAC/OSCC...
March 11, 2024: Radiotherapy and Oncology
https://read.qxmd.com/read/38473874/clinical-relevance-of-tumour-infiltrating-immune-cells-in-her2-negative-breast-cancer-treated-with-neoadjuvant-therapy
#24
JOURNAL ARTICLE
Cristina Arqueros, Alberto Gallardo, Silvia Vidal, Rubén Osuna-Gómez, Ariadna Tibau, Olga Lidia Bell, Teresa Ramón Y Cajal, Enrique Lerma, Bárbara Lobato-Delgado, Juliana Salazar, Agustí Barnadas
Currently, therapy response cannot be accurately predicted in HER2-negative breast cancer (BC). Measuring stromal tumour-infiltrating lymphocytes (sTILs) and mediators of the tumour microenvironment and characterizing tumour-infiltrating immune cells (TIICs) may improve treatment response in the neoadjuvant setting. Tumour tissue and peripheral blood samples were retrospectively collected from 118 patients, and sTILs were evaluated. Circulating exosomes and myeloid-derived suppressor cells were determined by flow cytometry...
February 23, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38469233/a-facs-based-novel-isolation-technique-identifies-heterogeneous-ctcs-in-oral-squamous-cell-carcinoma
#25
JOURNAL ARTICLE
Anshika Chauhan, Arnab Pal, Meenakshi Sachdeva, Geeta S Boora, Monil Parsana, Jaimanti Bakshi, Roshan Kumar Verma, Radhika Srinivasan, Debajyoti Chatterjee, Arindam Maitra, Sushmita Ghoshal
PURPOSE: Isolating circulating tumour cells (CTCs) from the blood is challenging due to their low abundance and heterogeneity. Limitations of conventional CTC detection methods highlight the need for improved strategies to detect and isolate CTCs. Currently, the Food and Drug Administration (FDA)-approved CellSearch™ and other RUO techniques are not available in India. Therefore, we wanted to develop a flexible CTC detection/isolation technique that addresses the limitation(s) of currently available techniques and is suitable for various downstream applications...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38466190/liquid-biopsy-of-oesophageal-squamous-cell-carcinoma-implications-in-diagnosis-prognosis-and-treatment-monitoring
#26
REVIEW
Mei-Juan Hao, Zhi-Yuan Cheng, Ye Gao, Lei Xin, Chu-Ting Yu, Ting-Lu Wang, Zhao-Shen Li, Luo-Wei Wang
Oesophageal squamous cell carcinoma (ESCC) is a common malignant tumour of the gastrointestinal tract. Early detection and access to appropriate treatment are crucial for the long-term survival of patients. However, limited diagnostic and monitoring methods are available for identifying early stage ESCC. Endoscopic screening and surgical resection are commonly used to diagnose and treat early ESCC. However, these methods have disadvantages, such as high recurrence, lethality, and mortality rates. Therefore, methods to improve early diagnosis of ESCC and reduce its mortality rate are urgently required...
March 11, 2024: Scandinavian Journal of Gastroenterology
https://read.qxmd.com/read/38457477/a-novel-method-for-the-isolation-of-single-cells-mimicking-circulating-tumour-cells-adhered-on-smart-bio-surface-slides-by-laser-capture-microdissection
#27
JOURNAL ARTICLE
Grazia Visci, Doron Tolomeo, Angelo Lonoce, Aram Arshadi, Lorenzo Bascetta, Gianluca Trotta, Margot van Riel, Joris Robert Vermeesch, Roberta Carbone, Clelia Tiziana Storlazzi
In recent years, the importance of isolating single cells from blood circulation for several applications, such as non-invasive tumour diagnosis, the monitoring of minimal residual disease, and the analysis of circulating fetal cells for prenatal diagnosis, urged the need to set up innovative methods. For such applications, different methods were developed. All show some weaknesses, especially a limited sensitivity, and specificity. Here we present a new method for isolating a single or a limited number of cells adhered to SBS slides (Tethis S...
2024: PloS One
https://read.qxmd.com/read/38455766/circulating-serum-mir-362-3p-and-mir-6721-5p-as-potential-biomarkers-for-classification-patients-with-adult-type-diffuse-glioma
#28
JOURNAL ARTICLE
Magdalena Niemira, Agnieszka Bielska, Karolina Chwialkowska, Justyna Raczkowska, Anna Skwarska, Anna Erol, Anna Zeller, Gabriela Sokolowska, Damian Toczydlowski, Iwona Sidorkiewicz, Zenon Mariak, Joanna Reszec, Tomasz Lyson, Marcin Moniuszko, Adam Kretowski
According to the fifth edition of the WHO Classification of Tumours of the Central Nervous System (CNS) published in 2021, grade 4 gliomas classification includes IDH-mutant astrocytomas and wild-type IDH glioblastomas. Unfortunately, despite precision oncology development, the prognosis for patients with grade 4 glioma remains poor, indicating an urgent need for better diagnostic and therapeutic strategies. Circulating miRNAs besides being important regulators of cancer development could serve as promising diagnostic biomarkers for patients with grade 4 glioma...
2024: Frontiers in Molecular Biosciences
https://read.qxmd.com/read/38453889/targeting-metastasis-initiating-cancer-stem-cells-in-gastric-cancer-with-leukaemia-inhibitory-factor
#29
JOURNAL ARTICLE
Lornella Seeneevassen, Anissa Zaafour, Elodie Sifré, Coralie Genevois, Tra Ly Nguyen, Yasmine Pobiedonoscew, Alban Giese, Jérôme Guignard, Camille Tiffon, Benoit Rousseau, Anne-Aurélie Raymond, Geneviève Belleannée, Hélène Boeuf, Caroline Gronnier, Océane C B Martin, Julie Giraud, Philippe Lehours, Pierre Dubus, Christine Varon
Gastric cancer's (GC) bad prognosis is usually associated with metastatic spread. Invasive cancer stem cells (CSC) are considered to be the seed of GC metastasis and not all CSCs are able to initiate metastasis. Targeting these aggressive metastasis-initiating CSC (MIC) is thus vital. Leukaemia inhibitory factor (LIF) is hereby used to target Hippo pathway oncogenic members, found to be induced in GC and associated with CSC features. LIF-treated GC cell lines, patient-derived xenograft (PDX) cells and/or CSC tumourspheres underwent transcriptomics, laser microdissection-associated proteomics, 2D and 3D invasion assays and in vivo xenograft in mice blood circulation...
March 7, 2024: Cell Death Discovery
https://read.qxmd.com/read/38451242/circulating-cell-free-dna-based-biomarkers-for-prognostication-and-disease-monitoring-in-adrenocortical-carcinoma
#30
JOURNAL ARTICLE
Juliane Lippert, Gabrielle Smith, Silke Appenzeller, Laura-Sophie Landwehr, Alessandro Prete, Sonja Steinhauer, Miriam Asia, Hanna Urlaub, Yasir S Elhassan, Stefan Kircher, Wiebke Arlt, Martin Fassnacht, Barbara Altieri, Cristina L Ronchi
Adrenocortical carcinoma (ACC) is a rare aggressive cancer with heterogeneous behaviour. Disease surveillance relies on frequent imaging, which comes with significant radiation exposure. The aim of the study was to investigate the role of circulating cell-free DNA (ccfDNA)-related biomarkers (BM) for prognostication and monitoring of ACC. We investigated 34 patients with ACC and 23 healthy subjects (HS) as controls. ccfDNA was extracted by commercial kits and ccfDNA concentrations quantified by fluorimeter (BM1)...
March 7, 2024: European Journal of Endocrinology
https://read.qxmd.com/read/38422618/liquid-biopsy-based-circulating-tumour-ct-dna-analysis-of-a-spectrum-of-myeloid-and-lymphoid-malignancies-yields-clinically-actionable-results
#31
JOURNAL ARTICLE
Douglas A Mata, Jessica K Lee, Vignesh Shanmugam, Chelsea B Marcus, Alexa B Schrock, Erik A Williams, Lauren L Ritterhouse, Richard A Hickman, Tyler Janovitz, Nimesh R Patel, Benjamin R Kroger, Jeffrey S Ross, Kamran M Mirza, Geoffrey R Oxnard, Jo-Anne Vergilio, Julia A Elvin, Jamal K Benhamida, Brennan Decker, Mina L Xu
AIMS: Liquid biopsy (LBx)-based next-generation sequencing (NGS) of circulating tumour DNA (ctDNA) can facilitate molecular profiling of haematopoietic neoplasms (HNs), particularly when tissue-based NGS is infeasible. METHODS AND RESULTS: We studied HN LBx samples tested with FoundationOne Liquid CDx, FoundationOne Liquid, or FoundationACT between July 2016 and March 2022. We identified 271 samples: 89 non-Hodgkin lymphoma (NHL), 43 plasma-cell neoplasm (PCN), 41 histiocytoses, 27 myelodysplastic syndrome (MDS), 25 diffuse large B-cell lymphoma (DLBCL), 22 myeloproliferative neoplasm (MPN), 14 Hodgkin lymphoma (HL), and 10 acute myeloid leukaemia (AML)...
February 29, 2024: Histopathology
https://read.qxmd.com/read/38416302/poor-patient-outcome-correlates-with-active-engulfment-of-cytokeratin-positive-ctcs-within-cancer-associated-monocyte-population-in-lung-cancer
#32
JOURNAL ARTICLE
A P Wiegmans, E Ivanova, V Y Naei, J Monkman, J Fletcher, W Mullally, M E Warkiani, K O'Byrne, A Kulasinghe
High rates of mortality in non-small cell lung cancer lung cancer is due to inherent and acquired resistance to systemic therapies and subsequent metastatic burden. Metastasis is supported by suppression of the immune system at secondary organs and within the circulation. Modulation of the immune system is now being exploited as a therapeutic target with immune checkpoint inhibitors. The tracking of therapeutic efficacy in a real-time can be achieved with liquid biopsy, and evaluation of circulating tumour cells and the associated immune cells...
February 28, 2024: Clinical & Experimental Metastasis
https://read.qxmd.com/read/38405859/functional-characterisation-of-the-atoh1-molecular-subtype-indicates-a-pro-metastatic-role-in-small-cell-lung-cancer
#33
Alessia Catozzi, Maria Peiris-Pagès, Sam Humphrey, Mitchell Revill, Derrick Morgan, Jordan Roebuck, Yitao Chen, Bethan Davies-Williams, Alice Lallo, Melanie Galvin, Simon P Pearce, Alastair Kerr, Lynsey Priest, Victoria Foy, Mathew Carter, Rebecca Caeser, Joseph Chan, Charles M Rudin, Fiona Blackhall, Kristopher K Frese, Caroline Dive, Kathryn L Simpson
Molecular subtypes of Small Cell Lung Cancer (SCLC) have been described based on differential expression of transcription factors (TFs) ASCL1, NEUROD1 , POU2F3 and immune-related genes. We previously reported an additional subtype based on expression of the neurogenic TF ATOH1 within our SCLC Circulating tumour cell- Derived eXplant (CDX) model biobank. Here we show that ATOH1 protein was detected in 7/81 preclinical models and 16/102 clinical samples of SCLC. In CDX models, ATOH1 directly regulated neurogenesis and differentiation programs consistent with roles in normal tissues...
February 17, 2024: bioRxiv
https://read.qxmd.com/read/38398148/interleukin-6-as-a-predictive-factor-of-pathological-response-to-flot-regimen-systemic-treatment-in-locally-advanced-gastroesophageal-junction-or-gastric-cancer-patients
#34
JOURNAL ARTICLE
Katarzyna Marcisz-Grzanka, Beata Kotowicz, Aleksandra Nowak, Mariola Winiarek, Malgorzata Fuksiewicz, Maria Kowalska, Andrzej Tysarowski, Tomasz Olesinski, Jakub Palucki, Urszula Sulkowska, Agnieszka Kolasinska-Cwikla, Lucjan Stanislaw Wyrwicz
BACKGROUND: Perioperative treatment is a gold standard in locally advanced gastric cancer or GEJ cancer in the Western population. Unfortunately, the response rate after neoadjuvant chemotherapy (NAC) remains limited. Moreover, there are currently no biomarkers enabling an individual prediction of therapeutic efficacy. The aim of this study was the identification of serum biomarkers of early response to NAC. METHODS: We conducted this prospective study in the MSCNRIO in Warsaw, Poland...
February 12, 2024: Cancers
https://read.qxmd.com/read/38395374/suppression-of-hypoxia-induced-cav1-autophagic-degradation-enhances-nanoalbumin-paclitaxel-transcytosis-and-improves-therapeutic-activity-in-pancreatic-cancer
#35
JOURNAL ARTICLE
Xiangli Bai, Jia Xiong, Lin Li, Chao Yu, Chengyi Sun
Nanoalbumin-paclitaxel (nab-paclitaxel) is a standard chemotherapy for pancreatic cancer but has shown limited efficacy. However, the mechanism through which circulating nab-paclitaxel passes through the tumour vascular endothelium has not been determined. In our study, a new nonradioactive and highly sensitive method for analysing nab-paclitaxel transcytosis was established. Based on these methods, we found that hypoxia significantly enhanced the autophagic degradation of CAV1 and therefore attenuated caveolae-mediated nab-paclitaxel transcytosis across endothelial cells (ECs)...
February 21, 2024: European Journal of Pharmacology
https://read.qxmd.com/read/38393090/cutaneous-plasmacytoma-with-systemic-metastases-in-a-cape-serotine-bat-laephotis-capensis
#36
Louise van der Weyden, Alida Avenant, Nicolize O'Dell
Despite their relatively long life-spans, reports of neoplasia in bats are rare and are limited to a handful of cases. In this report, we describe a 2-year-old female wild Cape serotine bat ( Laephotis capensis ) that had been caught by a domestic cat and presented with a skin mass over the chest area. Histopathological analysis of a subsequent biopsy revealed proliferating sheets of neoplastic round cells, occasionally appearing to form packets, supported by a fine, fibrovascular stroma. Marked nuclear pleomorphism was seen, as well as a high mitotic count...
February 5, 2024: Veterinary Sciences
https://read.qxmd.com/read/38392306/current-applications-and-challenges-of-next-generation-sequencing-in-plasma-circulating-tumour-dna-of-ovarian-cancer
#37
REVIEW
Ricardo Roque, Ilda Patrícia Ribeiro, Margarida Figueiredo-Dias, Charlie Gourley, Isabel Marques Carreira
Circulating tumour DNA (ctDNA) facilitates longitudinal study of the tumour genome, which, unlike tumour tissue biopsies, globally reflects intratumor and intermetastatis heterogeneity. Despite its costs, next-generation sequencing (NGS) has revolutionised the study of ctDNA, ensuring a more comprehensive and multimodal approach, increasing data collection, and introducing new variables that can be correlated with clinical outcomes. Current NGS strategies can comprise a tumour-informed set of genes or the entire genome and detect a tumour fraction as low as 10-5 ...
January 31, 2024: Biology
https://read.qxmd.com/read/38384811/editorial-circulating-biomarkers-in-prostate-cancer
#38
EDITORIAL
Masayoshi Nagata, Shigeo Horie, Yafeng Ma
No abstract text is available yet for this article.
2024: Frontiers in Oncology
https://read.qxmd.com/read/38382536/dapagliflozin-alleviates-high-glucose-induced-injury-of-endothelial-cells-via-inducing-autophagy
#39
JOURNAL ARTICLE
Gen Li, Ningxin Hou, Huagang Liu, Jun Li, Hongping Deng, Hongwen Lan, Sizheng Xiong
Hyperglycaemia is a key factor in the progression of diabetes complications. Dapagliflozin (DAPA), a new type of hypoglycaemic agent, has been shown to play an important role in anti-apoptotic, anti-inflammatory and antioxidant activities. Previous studies have demonstrated an endothelial protective effect of DAPA, but the underlying mechanism was still unclear. Autophagy is a homeostatic cellular mechanism that circulates unfolded proteins and damaged organelles through lysosomal dependent degradation...
April 2024: Clinical and Experimental Pharmacology & Physiology
https://read.qxmd.com/read/38365286/investigating-the-association-between-genetically-proxied-circulating-levels-of-immune-checkpoint-proteins-and-cancer-survival-protocol-for-a-mendelian-randomisation-analysis
#40
JOURNAL ARTICLE
Tessa Bate, Richard M Martin, James Yarmolinsky, Philip C Haycock
INTRODUCTION: Compared with the traditional drug development pathway, investigating alternative uses for existing drugs (ie, drug repurposing) requires substantially less time, cost and resources. Immune checkpoint inhibitors are licensed for the treatment of certain breast, colorectal, head and neck, lung and melanoma cancers. These drugs target immune checkpoint proteins to reduce the suppression of T cell activation by cancer cells. As T cell suppression is a hallmark of cancer common across anatomical sites, we hypothesise that immune checkpoint inhibitors could be repurposed for the treatment of additional cancers beyond the ones already indicated...
February 15, 2024: BMJ Open
keyword
keyword
53982
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.